150 W 4th Ave
Vancouver, BC V5Y 1G6
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at SABCS® 2026

2026-11-25

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) today announced an upcoming poster presentation of ABCL635 Phase 1/2 data at the San Antonio Breast Cancer Symposium® (SABCS), to be held December 8 to 11, 2026 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Details on AbCellera's poster presentation at SABCS are as follows:

Title: Safety and Efficacy of ABCL635, an NK3R Monoclonal Antibody Antagonist for the Treatment of Vasomotor Symptoms: A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study
Presentation Number: P1-4-30
Date and Time: Wednesday, December 9 from 12:30 p.m. to 2:00 p.m. CT
Location: Exhibit Hall, Henry B. Gonzalez Convention Center

AbCellera will present efficacy and safety data from its Phase 1/2 trial, including new data on change in vasomotor symptoms (VMS) frequency and severity in the first study week, as well as in participants over age 65.

About ABCL635

ABCL635 is a potential first-in-class investigational antibody drug candidate for the non-hormonal, long-acting treatment of moderate and severe VMS, commonly known as hot flashes, due to menopause. ABCL635 selectively

targets NK3R, a complex transmembrane protein found on hypothalamic KNDy neurons that helps regulate body temperature. ABCL635 is AbCellera's first program from its GPCR and ion channel platform to advance into the clinic. Additional details are available at **www.abcellera.com/pipeline**.

The Phase 2 portion of the Phase 1/2 trial of ABCL635 (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled trial in postmenopausal women with moderate and severe VMS due to menopause evaluating safety and efficacy of ABCL635.

ABCL635 is also being developed for the treatment of VMS due to endocrine therapy for breast cancer.

About VMS

Hot flashes and night sweats, known as VMS, are the most common menopausal symptoms, impacting up to 80% of women. Many women rate their VMS as moderate and severe, characterized by intense feelings of heat that lead to sweating, chills, and interrupted sleep. VMS are the most frequent reason for seeking medical care for menopause and can persist for over four years after the final menstrual period. VMS have a significant impact on quality of life, are associated with cardiovascular disease risk, and result in lost productivity, career advancement, and income. It is estimated that approximately 12 million women in the US experience moderate and severe VMS, of which more than six million seek treatment.

VMS caused by endocrine therapy may disrupt daily life and compromise treatment adherence in women with breast cancer. Menopause hormone therapy is contraindicated in this population, warranting the need for safe and effective non-hormonal treatment options.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. For more information, please visit **www.abcellera.com**.

AbCellera Forward-looking Statements

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study

comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Inquiries

Media: Tiffany Chiu; **media@abcellera.com**, +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; **partnering@abcellera.com**, +1(604)559-9005
Investor Relations: Peter Ahn; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.